PHARMACY **BENEFACT**

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Jamp Pharma Corporation and Sandoz Canada Inc. that the shortage for Jamp-Timolol 0.5% Ophthalmic Solution (DIN 02447800) and Sandoz Timolol 0.5% Ophthalmic Solution (DIN 02166720) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the Least Cost Alternative (LCA) price policy will be reapplied to the following grouping effective **December 1, 2021**. The following grouping was removed from the Critical Supply Product List **November 2, 2021**.

TIMOLOL MALEATE

0.5 % OPHTHALMIC SOLUTION

00000755834	APO-TIMOP	APX	\$1.2140
00002447800	JAMP-TIMOLOL	JPC	\$1.2140
00002166720	SANDOZ TIMOLOL MALEATE	SDZ	\$1.2140
00000451207	TIMOPTIC	ELV	\$4.1390

Alberta Blue Cross has been advised by Auro Pharma Inc. that the shortage for Auro-Ziprasidone 40 mg Capsule (DIN 02449552) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 9, 2021**. The following grouping was removed from the Critical Supply Product List **November 9, 2021**.

ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE

40 MG CAPSULE

00002449552	AURO-ZIPRASIDONE	AUR	\$1.5786
00002298600	ZELDOX	UJC	\$2.1707

Temporary benefits added to the ADBL

Due to the unavailability of Apo-Amitriptyline 25 mg Tablet (DIN 02403145) manufactured by Apotex Inc. and Elavil 25 mg Tablet (DIN 00335061) manufactured by AA Pharma Inc., pms-Amitriptyline 25 mg Tablet (DIN 00654515) will be considered as a temporary benefit for the *ADBL*. This grouping was added to the Critical Supply Product List **October 29, 2021**.

As of **October 29, 2021**, all claims for pms-Amitriptyline 25 mg Tablet (DIN 00654515) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **www.ab.bluecross.ca/providers/pharmacy-home.php**.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

continued next page





PHARMACY BENEFACT

continued from previous page

Due to the unavailability of Teva-Ectosone 0.1% Scalp Lotion (DIN 00653217) manufactured by Teva Canada Limited, Betaderm 0.1% Scalp Lotion (DIN 00716634) will be considered as a temporary benefit for the *ADBL*. This grouping was added to the Critical Supply Product List **November 4, 2021**.

As of **November 4, 2021**, all claims for Betaderm 0.1% Scalp Lotion (DIN 00716634) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **www.ab.bluecross.ca/providers/pharmacy-home.php**.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free) Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



